Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Kura Oncology Inc.
DescriptionInhibitor of MAP kinase 1 (MAPK1; ERK-2) and MAPK3 (ERK-1)
Molecular Target MAP kinase 1 (MAPK1) (ERK-2) ; MAP kinase 3 (MAPK3) (ERK-1)
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPreclinical
Standard IndicationSolid tumors
Indication DetailsTreat solid tumors with BRAF mutations; Treat solid tumors with KRAS mutations; Treat solid tumors with NRAS mutations
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today